Technology Details:
This inactivated vaccine has been developed for control of equine herpesvirus-1 infection in horses. This vaccine was developed using field strain of equine herpes virus-1. EHV-1 is responsible for heavy economic losses to the equine industry. Healthy horses acquire infections mostly through the respiratory tract. In a national assessment of EHV-1 infection amongst Equidae in India, 13.5% of serum samples were found seropositive. The killed vaccine is recommended for immunoprophylaxis in countries where there is a general ban on the live vaccine. This vaccine will serve as an alternative for control of the disease. Equiherpabort vaccine is a formaline inactivated vaccine prepared from an indigenous EHV-1 (strain Hisar-90-7), grown in VERO Cell culture. This is an oil emulsion mannide monooleate (OEMM) EHV-1 vaccine. This vaccine is intended for all equine species especially for pregnant mares. Protective immunization response of this vaccine was recorded in experimental field trials conducted in pregnant mares. This vaccine provides very good protective immunity against abortions due to EHV1. This vaccine showed comparable results with respect to the commercial vaccine. For pregnant mares, aseptically administer one 2-mL dose intramuscularly during the 5th, 7th and 9th months of pregnancy. Revaccinate annually at the 5th, 7th and 9th months of pregnancy. This vaccine will help in the decrease in the occurrence of abortions, paralysis, perinatal foal mortality and respiratory disease due to EHV-1.